LP
ABUS icon

LMR Partners’s Arbutus Biopharma ABUS Stock Holding History

LMR Partners’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-158,249
Closed -$517K – 1333
2024
Q4 		$517K Sell
158,249
-38,776
-20% -$143K ﹤0.01% 836
2024
Q3 		$759K Sell
197,025
-58,376
-23% -$224K 0.01% 773
2024
Q2 		$789K Buy
255,401
+195,401
+326% +$586K 0.01% 707
2024
Q1 		$155K Hold
60,000
– – ﹤0.01% 892
2023
Q4 		$150K Buy
60,000
+2,667
+5% +$5.22K ﹤0.01% 744
2023
Q3 		$116K Hold
57,333
– – ﹤0.01% 669
2023
Q2 		$132K Sell
57,333
-2,667
-4% -$6.94K ﹤0.01% 605
2023
Q1 		$182K Hold
60,000
– – ﹤0.01% 870
2022
Q4 		$140K Buy
60,000
+6,060
+11% +$14.5K ﹤0.01% 1021
2022
Q3 		$103K Hold
53,940
– – ﹤0.01% 1049
2022
Q2 		$146K Sell
53,940
-6,060
-10% -$15.5K ﹤0.01% 1085
2022
Q1 		$179K Hold
60,000
– – ﹤0.01% 1155
2021
Q4 		$233K Buy
+60,000
New +$233K ﹤0.01% 1055
2021
Q2 		– Sell
-42,171
Closed -$140K – 1090
2021
Q1 		$140K Sell
42,171
-60,594
-59% -$234K ﹤0.01% 824
2020
Q4 		$365K Sell
102,765
-5,147
-5% -$18K 0.01% 374
2020
Q3 		$338K Hold
107,912
– – 0.01% 303
2020
Q2 		$196K Buy
+107,912
New +$177K ﹤0.01% 489
2019
Q4 		– Sell
-29,104
Closed -$44K – 394
2019
Q3 		$44K Hold
29,104
– – ﹤0.01% 380
2019
Q2 		$61K Buy
+29,104
New +$74.5K ﹤0.01% 372
2014
Q4 		– Sell
-15,895
Closed -$337K – 359
2014
Q3 		$337K Buy
+15,895
New +$260K 0.03% 207
2014
Q2 		– Sell
-15,178
Closed -$329K – 455
2014
Q1 		$329K Buy
+15,178
New +$273K 0.05% 176

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
FC
Foursixthree Capital New York $268M AUM 115.24% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return

LMR Partners's ABUS Position: Q1 2025 in Review

LMR Partners sold out of Arbutus Biopharma (ABUS) in Q1 2025, closing a stake of 158,249 shares — an estimated $517K sold.

LMR Partners first reported a position in ABUS in Q1 2014 and held it in 21 quarters. The position peaked at $789K in Q2 2024. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2025.

  • LMR Partners reported no remaining Arbutus Biopharma position as of Q1 2025 after selling out during the quarter.
  • LMR Partners sold 158,249 Arbutus Biopharma shares in Q1 2025, an estimated $517K.
  • LMR Partners first reported a position in Arbutus Biopharma in Q1 2014 and held it in 21 quarters.
  • LMR Partners's Arbutus Biopharma position peaked at $789K in Q2 2024.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2025.

Based on LMR Partners's 13F filing for Q1 2025, filed 15 May 2025.